RDI models perform well with Phidisa cohort in South Africa

Dear RDI subscriber,

The testing of the RDIaEUR(TM)s models as predictors of treatment response with data from the Phidisa cohort in South Africa have been published in the South African Journal of HIV Medicine.

The 402 patients in the cohort were changing therapy due to virological failure or toxicity, mostly from 1st to 2nd line regimens. The models, which do not require a genotype for their predictions, were used to predict whether or not the new regimen introduced in the clinic would achieve virological suppression or not.

The models achieved accuracy (area under the receiver-operator curve) of 0.72 compared with 0.80 for a global test set and typically 0.55-0.60 for genotyping with rules based interpretation. They were able to identify alternative, available 3-drug regimens that were predicted to achieve virological suppression in 62% of the cases where the new regimen introduced in the clinic failed.

The predictive accuracy of the models for these South African patients together with the results of previous studies suggest that HIV-TRePS has the potential to optimise treatment selection and reduce virological failure in different patient populations in resource-limited settings, without the use of a genotype.

The paper itself can be found here:


We hope you find the paper interesting and that you will alert your colleagues and contacts, particularly those in resource-limited settings, to the existence and potential utility of HIV-TRePS.

Sign In or Register now at: https://www.hivrdi.org/treps

The RDI team.

Date published: 7th July 2016


Join the RDI mailing list

Enter your email address below to start receiving the RDI newsletter.

You can unsubscribe at any time. View the RDI privacy policy.